PLASMA PROTEASE C1-INHIBITOR TREATMENT MARKET ANALYSIS

Hereditary angioedema (HAE) is an autosomal disorder characterized by low levels of functional C1 esterase inhibitor protein. Purified concentrate of C1 esterase inhibitors are used in HAE affected patients for the prophylactic and acute attack treatment of HAE. Several plasma protease C1-inhibitors such as Cinryze, Firazyr, Kalbitor, and Berinet have been approved for the prophylactic and acute attack treatment of hereditary angioedema.

Global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 3,289.5 million in 2020 and is expected to exhibit a CAGR of 18.2% during the forecast period (2020-2027).

Figure 1. Global Plasma Protease C1-inhibitor Treatment Market Share (%), by Drug Type, 2020

To learn more about this report, request sample copy

Global Plasma Protease C1-inhibitor Treatment Market – Drivers

The increasing focus of biopharmaceutical companies on development of effective plasma protease C1-inhibitor treatment drugs/therapy treating various health conditions such as HAE, diabetic macular edema (DME), and others, is expected to drive growth of the plasma protease C1-inhibitor treatment market. Several kallikrein inhibitor therapies are currently in preclinical and clinical development stages. For instance, in September 2019, Oxurion released positive topline data from a phase 1 study of THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME). Moreover, in December 2019, KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced results of the Phase 2 clinical trial evaluating the use of KVD001 in patients with diabetic macular edema (DME).

Furthermore, adoption of inorganic growth strategies such as partnerships and collaborations, in order to develop innovative protease C1-inhibitor treatment is significantly contributing to the growth of global plasma protease C1-inhibitor treatment market. For instance, in October 2017, KalVista Pharmaceuticals, Inc. entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada for KVD001 (investigational plasma kallikrein inhibitors). The company’s investigational intravitreal (IVT) injection candidate is currently in development for potential treatment of diabetic macular edema (DME).

Global Plasma Protease C1-inhibitor Treatment Market - Restraints

However, the rare occurrence of the HAE makes it difficult for efficient diagnosis and opting alternative therapies to control the disease are the major factors that are expected to restrain the plasma protease c1-inhibitor treatment market growth over the forecast period.

Figure 2. Global Plasma Protease C1-inhibitor Treatment Market Share (%), by Region, 2020

To learn more about this report, request sample copy

Global Plasma Protease C1-inhibitor Treatment Market - Regional Analysis

On the basis of region, the global plasma protease C1-inhibitor treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America plasma protease C1-inhibitor treatment market is expected to exhibit significant growth during the forecast period, owing to increasing approvals of novel therapies by the regulatory agencies such as the U.S. Food and Drug Administration. For instance, in 2014, the U.S. FDA approved Pharming Healthcare’s Ruconest, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE.

Key Players:

Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.